RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 Pipeline Review, H2 2017 [Report Updated: 07112017] Prices from USD $3500
RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 Pipeline Review, H2 2017
Summary
RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report RAC Beta SerineThreonine Protein Kinase Pipeline Review, H2 2017, outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 RACbeta serine/threonineprotein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKTmTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Breast Cancer, Endometrial Cancer, NonSmall Cell Lung Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, SmallCell Lung Cancer, Colorectal Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Prostate Cancer, Thymoma Thymic Epithelial Tumor, Anal Cancer, Brain Cancer, Colon Cancer, Congenital Vascular Malformation, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor GIST, Glioblastoma Multiforme GBM, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease, Soft Tissue Sarcoma and Solid Tumor.
Furthermore, this report also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1
The report reviews RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
